Related by context. Frequent words. (Click for all words.) 71 Commences Phase 71 Preclinical Data 71 Drug Candidate 71 Initiates Phase II 70 Clinical Trial Results 70 Presents Positive 70 Monoclonal Antibody 69 Small Molecule 69 Chronic Hepatitis C 69 Phase III Clinical Trial 69 Completes Enrollment 69 Metastatic Melanoma 69 Initiates Phase 69 Patient Enrollment 68 Recombinant Human 68 Initiate Phase 68 Develop Novel 67 Gastric Cancer 67 Phase III Trial 67 FDA Accepts 67 RNAi Therapeutics 67 Pulmonary Arterial Hypertension 67 Pivotal Study 66 Pivotal Phase 66 FDA Clears 66 Pivotal Trial 66 Gene Mutation 66 Single Dose 66 Flagship Product 65 Epratuzumab 65 Ofatumumab 65 Exclusive License 65 Combination Therapy 65 II Clinical Trial 65 Announces Initiation 65 Achieves Milestone 65 Inhibits 65 Announces FDA Clearance 65 Chronic Hepatitis B 64 Autoimmune Disease 64 Cancer Vaccines 64 Drug Resistant 64 Targeted Therapy 64 Pivotal Phase III 64 Patent Covering 64 Renal Cell Carcinoma 64 Significantly Improves 64 Cancer Therapies 64 Metastatic Colorectal Cancer 64 Study Demonstrates 64 Chronic Lymphocytic Leukemia 64 Inovio Pharmaceuticals 64 ALN TTR 64 Closes Financing 64 Monoclonal Antibodies 64 refractory chronic lymphocytic 64 Completes Financing 64 Insulin Resistance 64 Tesetaxel 63 Amino Acid 63 J Am Acad 63 Obstet Gynecol 63 Shows Promise 63 Voreloxin 63 Well Tolerated 63 Arch Neurol 63 Newly Diagnosed 63 Malaria Vaccine 63 Secures Financing 63 Patent Issued 63 Announces Publication 63 Prostate Cancer Patients 63 Oligonucleotide 63 Bortezomib 63 Inc Therapeutic Competitors 63 Joint Surg Am 63 Report Analyzes 62 Child Adolesc Psychiatry 62 humanized anti 62 FDA Clearance 62 Joint Surg Br 62 Meta Analysis 62 Nephrol 62 Monotherapy 62 Phase Ib II 62 Polymorphism 62 Advanced Prostate Cancer 62 Seamless Integration 62 Develop Next Generation 62 targeting CD# 62 Receives FDA Clearance 62 Ambrisentan 62 Significantly Reduces 62 MITTEILUNG UEBERMITTELT VON BUSINESS 62 Influenza Vaccine 62 Smallpox Vaccine 62 Elderly Patients 62 Dapagliflozin 62 Intellectual Property Portfolio 62 MorphoSys AG FSE MOR 62 Immunogenicity